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Abstract The use of atypical antipsychotic drugs like
olanzapine is associated with side effects such as sedation
and depression-like symptoms, especially during the initial
period of the use. It is believed that the occurrence of these
undesirable effectsis mainly the result of the histamine
H1receptors blockade by olanzapine. In addition, use of
olanzapine increases the level of triglycerides in the blood,
which correlates with growing obesity. The aim of this study
was to investigate the influence of pitolisant – H3 histamine
antagonist - on subchronic olanzapine-induced depresion-like
symptoms, sedation and hypertriglicerydemia. Forced swim
test was conducted to determinate depressive-like effect of
olanzapine and antidepressive-like activity during the co-
administered pitolisant. The test was performed after the first
and fifteenth day of the treatment of the mice. The spontane-
ous activity of the mice was measured on the fourteenth day of
the treatment with a special, innovative RFID-system (Radio-
frequency identification system) – TraffiCage (TSE-Systems,
Germany). Triglyceride levels were determined on the
sixteenth day of the experiment after 15 cycles of drug admin-
istration. Daily olanzapine treatment (4 mg/kg b.w., i.p., d.p.d)
for 15 days significantly induces sedation (p < 0.05) and pro-
longs immobility time in forced swim tests (FST) in mice
(p < 0.05); and also elevates the level of triglycerides
(p < 0.05). Administration of pitolisant (10 mg/kg b.w., i.p.)
subsequentto olanzapine normalizes these adverse effects.
This study presents a promising alternative for counteracting
some behavioral changes and metabolic disturbances which
occur in the early period of treatment with antipsychotic
drugs.
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Introduction
Olanzapine is one of the most commonly used atypical drugs
for schizophrenia (Podogrodzka and Jarema 2010), and one of
the strongest antagonists of the H1 histamine receptors (H1R)
(Richelson and Souder 2000). The use of atypical antipsychot-
ic drugs like olanzapine is associated with some side effects,
such as sedation and depression-like symptoms, especially in
the initial period of the use (Podogrodzka and Jarema 2010).
Atypical antipsychotics such as olanzapine may also increase
the level of triglycerides in the blood (Albaugh et al. 2011;
Misiak et al. 2014), which correlates with the development of
obesity during the treatment. This very unfavorable side effect
may be related to H1R (Reynolds and Kirk 2010) or H3 recep-
tor (H3R) (Deng et al. 2010). Data from literature confirm the
sedative effects of olanzapine in rodents, which increases pro-
portionally to the dose (Weston-Green et al. 2011). It is be-
lieved that the occurrence of these undesirable effects may be
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connected with the blockade of H1R (Miller 2004) and cho-
linergic M1 receptor (M1R) (Kane and Sharif 2008).
Therefore, the search for solutions to the problems of
sedation and depression-like symptoms occurring in the
initial period of atypical antypsychotics use is very sig-
nificant. Due to the belief, that simple blockade of his-
tamine action, by H1R antagonism may be responsible
for these effects, the possible solution might be connect-
ed with H3R ligands. In our research, we have explored
one of the H3R antagonists – Pitolisant (Wakix ®) - as
a potential target to minimize the adverse effects accom-
panying antypsychotic treatment.
The H3 receptor is a pre-synaptic autoreceptor that inhibits
synthesis andrelease of the histamine, and simultaneously a
heteroreceptor that inhibits other neurotransmitters such as
serotonin, noradrenaline and acetylcholine (Deng et al.
2010). It belongs to the G-protein-coupled receptor (GPCR)
family, with a complex structure and a large number of iso-
forms (Lovenberg et al. 1999; Hancock et al. 2003; Bakker
2004). The H3R are mainly expressed in the central nervous
system (CNS), especially in the areas connected with sleep,
cognition and homeostatic regulation (Haas et al. 2008).
Blockade of the H3R in the central nervous system results in
increased synthesis and disinhibition of the histamine release
(Brabant et al. 2013), a phenomenon explored further in this
study.
Many different ligands of H3R have been investigated in
recent years, and studies are still in progress (Łazewska and
Kieć-Kononowicz 2010; Łażewska and Kieć-Kononowicz
2014). One of the most heavily researched compounds is
Pitolisant, which is currently being tested in the third phase
of clinical trials (Łażewska and Kieć-Kononowicz
2014).Pitolisant is a selective inverse agonist for the H3R,
which enhances histaminergic activity in the brain of mice
(Ligneau et al. 2007). Its efficacy and safety in the treatment
of narcolepsy have been recently documented in a large
European multicentre double-blind, randomised, parallel-
group controlled trial (Dauvilliers et al. 2013). Pitolisant’s
wake-promoting activity was evidenced in excessive diurnal
sleepiness of patients with narcolepsy, Parkinson’s disease or
Obstructive Sleep Apnea/Hypopnea. The activity is character-
ized by a mean decrease on the Epworth Sleepiness Scale
(ESS) by about five units (Schwartz 2011). Moreover, the
procognitive activity of Pitolisant makes it a potential target
in diseases with cognitive deficits such as schizophrenia, de-
mentia or ADHD (attention deficit hyperactivity disorder)
(Schwartz 2011).Without question, its high therapeutic poten-
tial is the reason why we chose this compound for our
research.
The aim of this study was to investigate the influence of
pitolisant – an H3 histamine antagonist - on subchronic




Adult female Albino Swiss mice weighing 20–22 g were used
in the study. They were kept in environmentally controlled
rooms, in standard cages lit by an artificial light for 12 h each
day. Animals had free access to food and water except for the
time of the acute experiment. The randomly established ex-
perimental groups consisted of 12mice. The groupswere used
in the forced swim test (6 mice) and in the locomotor studies
(6 mice). Spontaneous activity was performed one day before
the forced swim test in asubchronic treated group of
animals (6 mice). Triglyceride levels were determined
only in the mice subjected to locomotor studies (6 mice). All
animal care and experimental procedures were carried out in
accordance with European Union and Polish legislation acts
concerning animal experimentation, and approved by the
Local Ethics Committee at the Jagiellonian University in
Cracow.
Experiment methods
Forced swim test (FST)
The forced swim test was conducted according to the method
described in the available literature (Porsolt et al. 1977; Pytka
et al. 2015a; Pytka et al. 2015b). Mice were forced to swim
individually in the glass cylinders (height 25 cm, diameter
10 cm) filled with 10 cm of water at a temperature of 23–
25 °C. The animals were placed into the cylinders for 6 min,
and the total duration of their immobility was recorded after a
2-min initial period. The test was performed after the first and
fifteenth day of thetreatment of the mice (the first day after
administration – acute treatment, or the sixteenth day after the
fifteenth administration – subchronic treatment).
Locomotor activity
Locomotor activity was recorded with an OptoM3multichan-
nel activity monitor (MultiDevice Software v1.3, Columbus
Instruments, USA) according to the method described by
Pytka et al. (Pytka et al. 2015c; Pytka et al. 2016). After being
placed into the cages individually, the mice had their activity
evaluated between the 2nd and the 6th minute. The time peri-
od chosen corresponded with the time interval considered in
the FST. Locomotor activity was evaluated as the distance
travelled by the animals while attempting to climb upward.
The test was performed after the first and fifteenth day of the
treatment of the mice (the first day after administration – acute
treatment, or the sixteenth day after the fifteenth administra-
tion – subchronic treatment).
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Spontaneous activity
The spontaneous activity of the mice was measured on the
fourteenth day of the treatment with a special, innovative
RFID-system (Radio-frequency identification system) –
TraffiCage (TSE-Systems, Germany). The test was conducted
according to the method described in the literature (Dudek
et al. 2015a; Dudek et al. 2015b; Dudek et al. 2016). The
animals had the transmitter (RFID) subcutaneously im-
planted, which tracked the time they spent in different
areas of the cage. The data obtained were then grouped
in a special computer program. Spontaneous activity
was measured starting from the fourteenth day of the
treatment at 1:00 pm to the fifteenth day at 9.00 am.
The mice were housed in cages in threes, with food and
water available ad libitum.
Biochemical analysis
Triglyceride levels were determined on the sixteenth day of
the experiment after 15 cycles of drug administration. The
mice were euthanized by cervical dislocation. The blood was
collected after decapitation and then centrifuged at 1200
rtf to obtain the serum. To determine triglyceride levels
in the serum, standard enzymatic spectrophotometric
tests (Biomaxima S.A. Lublin, Poland) were used. The
substrate was decomposed with enzymes appropriate for
the relevant product, and converted to a colored com-
pound. The coloration was proportional to the concen-
tration. Absorbance was measured at a wavelength of
500 nm.
Statistical analysis
The results obtained were analysed using a one-way
analysis of variance (ANOVA), followed by a Dunnet
post-hoc test, with the significance level set at 0.05
(FST and locomotor activity testsor triglyceride levels)
or by a Multiple t-test under the assumption that all
rows were sampled from populations with the same scatter
(spontaneous activity test). The outcomes were expressed as
the means ± standard error of the mean (SEM). Graph Pad
Prism 6.0 was used for data analysis.
Drugs, chemical reagents and other materials
Olanzapine or pitolisant were suspended in 1 % Tween 80.
The compounds o r veh i c l e we re admin i s t e r ed
Fig. 1 Forced swim test and locomotor activity. a Forced swim test after
one administration of the compound, b Locomotor activity after one
administration of the compound, c Forced swim test after fifteen
administrations of the compound, d Locomotor activity after fifteen
administrations of the compound, Mean ± SEM, n = 6; *P < 0.05 (one-
way ANOVA, Dunnet’s post hoc); * - Significant to control group –
0.2 ml 1 % Tween 80, ^ - Significant to olanzapine group – 2 mg/kg
b.w. olanzapine in acute tests and 2 × 2 mg/kg b.w. olanzapine in
subchronic tests
b
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intraperitoneally (i.p.) 30 min prior to the acute experiment. In
the pitolisant + olanzapine group, pitolisant was administered
15 min before olanzapine. Subchronic treatment was done at
about 9:00 am (0.2 ml Tween to control group, pitolisant -
10 mg/kg b.w. to pitolisant group, olanzapine - 2 mg/kg b.w.
to olanzapine group, pitolisant- 10 mg/kg b.w. and olanzapine
after 15 min- 2 mg/kg b.w. to pitolisant + olanzapine group)
and at about 1:00 pm (olanzapine group and pitolisant +
olanzapine group). The volume of the vehicle or the drug
solutions was 10 ml/kg.
Pitolisant was tested at dose 10 mg/kg b.w. According the
literature (Brabant et al. 2013; Uguen et al. 2013), at this dose,
it’s active but lacks the adverse effects. Olanzapine was tested
at dose 2 × 2 mg/kg b.w., which, according the literature data
(Albaugh et al. 2006; Kim et al. 2014), might induce metabol-
ic disorders in rodents. This dose is also suitable for the ob-
servation of decreasing in locomotor activity after olanzapine
in rodents (Klingerman et al. 2014). Additionally, due to a
much shorter half life of olanzapine in rodents compared to
man (van der Zwaal et al. 2008; Liebig et al. 2010), this dose
was shown to be appropriate to model pharmacodynamic ef-
fects of olanzapine in rodents (Kapur et al. 2003; Liebig et al.
2010). The olanzapine was delivered by Adamed Group
(Pieńków, Poland). The Pitolisant was synthesized at the
Department of Technology and Biotechnology of Drugs,




Pitolisant administered once, and for 15 consecutive days at a
dose of 10 mg/kg b.w. did not significantly affect the duration
of immobility in the forced swim test in mice. The results are
shown in Figs. 1a and c. This compound had also no effect on
locomotor activity; neither after one nor after fifteen adminis-
trations in mice. The results are presented in Figs. 1b and d.
Olanzapine administered to the mice once at a dose of 2 mg/
kg b.w., and for 15 daysat a dose 2 × 2 mg/kg b.w. significantly
increased the duration of immobility in the forced swim test in
comparison to the control group. The results are shown in
Fig. 1a and c. Olanzapine also significantly reduced locomotor
activity. The result are shown in Fig. 1b and d.
The administration of pitolisantat a single dose of 10mg/kg
30 min before a single dose of olanzapine (2 mg/kg b.w.) also
significantly affected immobility time in the FST. Subsequent
administration of the aforementioned drug sequence in mice
statistically significantly increased the duration of immobility
in comparison to the time determined in the control group in
the FST. It decreased locomotor activity as well. In contrast,
the results obtained in subchronic treatment after fifteen
Fig. 2 Spontaneous activity after fourteen administrations of the
compounds. a Comparison of control group to olanzapine group; b
Comparison of control group to pitolisant group; c Comparison of
control group to pitolisant + olanzapine group; d Comparison of
olanzapine group to pitolisant + olanzapine group. Mean ± SEM, n = 6;
Statistical significant: *P < 0.05 (Multiple t-test)
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administrations of both drugs (pitolisant 10 mg/kg b.w., and
after 30 min olanzapine 2 mg/kg b.w., and again after 4 h
olanzapine 2 mg/kg b.w.) showed that the administration of
pitolisant followed by that of olanzapine equalized the loco-
motor activity inmice; in comparison to the level ofmotility in
the control group, to which only pitolisant was administered
(Fig. 1d). More importantly, this combination of drugs signif-
icantly reduced immobility time to the level obtained in the
control group in the forced swim test in mice [one-way
ANOVA; F(3,20) = 4.226, P = 0.0181] (Fig. 1c).
Spontaneous activity
The control group of mice showed increased motor activity
after dark, while during the day their motility was reduced.
Both a single administration of olanzapine and its subchronic
administration resulted in a statistically significant reduction
of spontaneous mobility as compared to the control group in
both phases of the day- during the first hour of observation
(the bright phase), and from the fifth to the eighth hour of
observation (the dark phase). The results are shown in
Fig. 2a. Administration of the pitolisant did not significantly
affect spontaneous activity in the mice. In the study, the 20-h
mobility of the mice treated with pitolisant (10 mg/kg) was
very close to the mobility of the mice in the control group,
which received onlythe solvent (1 % Tween 80). The results
are shown in Fig. 2b. In the group treated with olanzapine and
pitolisant together, the mobility was indeed impaired - in the
first hours after the second dose of olanzapine, the mice
showed reduced motility compared to the control group, but
at the end of the dark phase and the following light phase, the
mobility was significantly increased. The results are shown in
Fig. 2c.When comparing the results of the 20-h observation of
spontaneous mobility of the group receiving olanzapine, and
the group receiving olanzapine plus pitolisant, it can be said
that the addition of pitolisant significantly increases the
motility of the mice in the dark phase and the lightphase that
follows. The results are shown in Fig. 2d. However, there was
significant compensation for the reduced motility of the
olanzapine-treated group in the dark phase, i.e. the natural
phase of very heavy activity in the mice.
Triglyceride levels
Intraperitoneal administration of olanzapine at a dose 2 × 2
mg/kg b.w. for 14 days resulted in a statistically significant
increase in the level of triglycerides in the mice serum. In the
group which was administered pitolisant (10 mg/kg b.w.) to-
gether with olanzapine, the triglyceride level wascomparable
to that in the control mice. Pitolisant administered alone had
no effect on the levels of triglycerides in mice. Figure 3 shows
the results.
Discussion
In the current study, the sub-chronic administration of
pitolisant in combination with olanzapine resulted in reduc-
tion of the immobility time in the FST in mice to the level
determined in the control group, which limits depression-like
symptoms. Moreover, pitolisant compensated for the sponta-
neous activity disturbances observed in the olanzapine-treated
group. Thus, our results confirm the beneficial effects of the
combined used for these compounds.
Studies using various H3R ligands have shown that these
compounds can favorably affect the levels of triglycerides in
animals (Hancock and Brune 2005; Malmlöf et al. 2006).
Atypical antipsychotics such as olanzapine may increase the
level of triglycerides in the blood (Albaugh et al. 2011; Misiak
et al. 2014), which correlates with the development of obesity
during the treatment. This very unfavorable side effect may be
related to the influence on the H1R (Reynolds and Kirk 2010)
Fig. 3 Triglyceride levels.
Mean ± SEM, n = 6; *P < 0.05
(one-way ANOVA, Dunnet’s post
hoc); * - Significant to control
group – 0.2 ml 1 % Tween 80, ^ -
Significant to olanzapine group –
2 × 2 mg/kg b.w. olanzapine after
subchronic treatment
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or H3R (Deng et al. 2010). A drug-induced decrease in H1R
act iv i ty may reduce the his tamine tone via the
H3autoreceptors, contributing to the weight gain problem. In
addition, atypical antipsychotics may affectfood intake by
influencing serotonine, noradrenaline and acetylcholine re-
lease via interactions with the H3R (Deng et al. 2010). The
observed results confirm that the increased response to the
histamine by using pitolisant may remove some metabolic
disturbances induced by the administration of olanzapine,
such as increased triglyceride levels in the serum. This fact
is extremely relevant due to the serious adverse metabolic
effects which develop in patients treated with atypical
neuroleptics.
It is important to mention that there are no reports on the
influence of pitolisant on triglyceride levels in literature.
Moreover, there is no information available on the combined
use of olanzapine and pitolisant in literature to date.
Undoubtedly, our preliminary studies with mice show that this
is an interesting combination of drugs. Based on the informa-
tion available, we only know that the co-administration of
olanzapine and pitolisant to healthy volunteers does not sig-
nificantly change the detected plasma level of the drugs in
comparison with their individual administration (Schwartz
2011). Additionally, taking into account the results of the
Porsolt test and the following motility measurement, we can
unequivocally conclude that pitolisant can reduce the
olanzapine–induced sedation and depression–like symptoms.
Conclusion
The observed results confirm that in patients treated with
olanzapine who experience unacceptable, adverse effects such
as excessive sedation or depression–like symptoms, the ad-
ministration of pitolisant can be attempted. Moreover, it can
be further explored whether this combination of drugs is able
to reduce or delay the onset of metabolic disorders induced by
olanzapine in patients. The presented preliminary study gives
a promising alternative for counteracting some antipsychotic-
associated behavioral and metabolic complications, and defi-
nitely needs further investigation.
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